Synairgen*: AstraZeneca commences AZD9412 Phase II trial in severe asthma (CORP) | The Mission Marketing Group*: Trading update (CORP) | Ideagen*: Prelims (CORP) | Amino Technologies*: Interims, placing and acquisition (CORP) | Staffline: EPS up 45% – strong momentum continues (BUY) | Gemfields*: Initial ruby resource – Montepuez mine (CORP) | Weatherly International*: Q4 operating results (CORP) | Fenner: Trading update (HOLD) | Sound Oil: Initiation of coverage – analyst i
22 Jul 2015
Morning Note
Synairgen plc (SNG:LON), 6.7 | Gemfields Group Limited (GEM:LON), 11.6 | LS WTI Oil ETC (WTI:LON), 1,684
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note
Synairgen plc (SNG:LON), 6.7 | Gemfields Group Limited (GEM:LON), 11.6 | LS WTI Oil ETC (WTI:LON), 1,684
- Published:
22 Jul 2015 -
Author:
Andrew Darley | David Buxton | Guy Hewett | Mark Paddon | Cavendish Research - Pages:
Synairgen*: AstraZeneca commences AZD9412 Phase II trial in severe asthma (CORP) | The Mission Marketing Group*: Trading update (CORP) | Ideagen*: Prelims (CORP) | Amino Technologies*: Interims, placing and acquisition (CORP) | Staffline: EPS up 45% – strong momentum continues (BUY) | Gemfields*: Initial ruby resource – Montepuez mine (CORP) | Weatherly International*: Q4 operating results (CORP) | Fenner: Trading update (HOLD) | Sound Oil: Initiation of coverage – analyst i